Gland Pharma has announced a USD 21 million investment in its step-down subsidiary, Gland Pharma USA, to acquire a 60% stake in the newly formed US-based Novelstar Pharma Inc. This strategic move aims to strengthen the company’s footprint in the US market, with the deal expected to close by October 31, 2026. Alongside this expansion, the board announced leadership changes, with Xingli Wang joining as a Non-Executive Director following the resignation of Wenjie Zhang.
Gland Pharma Expands US Footprint with USD 21 Million Novelstar Investment
USD 21 million investment for 60% stake in Novelstar Pharma Inc.
Completion target for acquisition set by October 31, 2026.
Reader Takeaway: Gland Pharma is aggressively targeting US market share through a new joint venture, though navigating integration remains critical.
What just happened
Gland Pharma has approved a capital infusion of USD 21 million into its wholly-owned step-down subsidiary, Gland Pharma USA Inc. The funds are earmarked for the acquisition of a 60% equity stake in a newly incorporated US entity, Novelstar Pharma Inc. The remaining 40% of Novelstar will be held by Fosun Pharma USA Inc., an affiliate of Gland Pharma’s promoter. The company has clarified that while the investment in the step-down subsidiary is an arm's-length transaction with a related party, the formation of the new subsidiary is aimed at broader US business expansion.
Why this matters
The US market represents a primary growth engine for Indian pharmaceutical companies. By establishing a presence through Novelstar, Gland Pharma is creating a structured platform to streamline its product offerings and operations in the American market. For investors, this signals the management’s focus on international scaling despite global pricing pressures in the generics sector.
Board and Governance Update
The company also confirmed significant leadership changes effective October 1, 2026. Non-Executive Director Wenjie Zhang has resigned due to pre-occupations. He is replaced by Xingli Wang, the President of Fosun Pharma, who joins the board as an Additional Non-Executive, Non-Independent Director. Dr. Jia Ai Zhang will also join the Stakeholders' Relationship & Share Transfer Committee as part of the broader committee realignment.
Risks to watch
Success hinges on the timely execution of the acquisition by October 31, 2026, and the subsequent operational integration of Novelstar. As with any cross-border expansion, regulatory compliance within the US FDA landscape and effective coordination with minority shareholder Fosun Pharma USA will be key operational focus areas.
What to track next
Investors should look for updates on the formal completion of the Novelstar stake acquisition and any subsequent product pipeline announcements linked to this new US entity.